Argenx launches $750M offering after PhII data drop

Dutch biotech ar­genx launched a $750 mil­lion of­fer­ing the same day it shared promis­ing da­ta from a Phase II study test­ing its on­ly ap­proved drug as a treat­ment for a rare neu­ro­log­i­cal dis­or­der.

The com­pa­ny al­so said Mon­day evening that in­vest­ment firm Bail­lie Gif­ford Over­seas Lim­it­ed is in­ter­est­ed in pur­chas­ing up to $200 mil­lion in shares as part of the of­fer­ing.

Its shares $ARGX jumped about 6% in trad­ing on Tues­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN